EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Canadian Endocrinologists′ Perspectives on Treatment With Thyroid Hormone Substitutions in Euthyroid and Hypothyroid Patients: A 2023 THESIS Questionnaire Survey

Anna Liu, Deric Morrison, Laszlo Hegedüs iD, Endre V Nagy iD, Enrico Papini iD, Petros Perros iD, Roberto Attanasio iD, Roberto Negro iD, Stan Van Uum iD, Birte Nygaard iD, Steen J Bonnema iD, Kamilla R Riis iD

Clinical Endocrinology · 2025

DOI: 10.1111/cen.70009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Anna Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Hypothyroidism, Endocrinologists, Thyroxine, Thyroid Hormones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was funded by a research grant from the Danish Medicines Agency, which had no role in the conceptualization, design, data collection, analysis, deci….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The practice of treating hypothyroid and euthyroid patients with thyroid hormones varies between countries, as observed in the recent surveys of European thyroid experts, THESIS. As part of the THESIS initiative, we investigated Canadian endocrinologists′ perspectives on this topic, focusing on combination therapy with either liothyronine (LT3) plus levothyroxine (LT4) or desiccated thyroid extract (DTE).

Design

Members of the Canadian Society of Endocrinology and Metabolism (CSEM) were invited to participate in an anonymous online survey.

Results

Out of 348 eligible CSEM members, 68 (19.5%) respondents were included in the analysis. All respondents used LT4 as the first‐line treatment for hypothyroid patients. Many respondents (64.7%) would consider LT4 + LT3 for patients on LT4 with persistent symptoms, whereas fewer would consider DTE (16.2%). Most respondents attributed persistent symptoms in LT4‐treated patients to psychosocial factors, comorbidities, or unrealistic expectations. Approximately half of the respondents stated that thyroid hormone therapy is never indicated for euthyroid patients. The remaining respondents considered thyroid hormones for euthyroid women with infertility and high thyroid antibody levels (36.8%), depression (13.2%), and growing goiter (7.4%).

Conclusions

Following current guidelines, LT4 tablet is the preferred treatment for hypothyroidism. Most respondents would consider triiodothyronine‐containing therapy for patients with persistent symptoms, preferring LT4 + LT3 over DTE. The number of endocrinologists considering combination therapy for hypothyroid patients in Canada was higher than in Europe. Finally, at variance with current guidelines, a fraction of the respondents would consider thyroid hormones in patients with non‐thyroidal conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypothyroidismEndocrinologistsThyroxineThyroid HormonesHormone Replacement TherapyHumansCanadaFemaleSurveys and QuestionnairesMaleAdultTriiodothyronineMiddle Aged

Stichwörter der Autor:innen

AutoimmunityCanadian Society of Endocrinology and MetabolismDesiccated thyroid extractHypothyroidismLevothyroxineLiothyronineQuestionnaire

Substanzen

ThyroxineThyroid HormonesTriiodothyronine

Autor:innen und Institutionen

  • Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Department of Medicine, Division of Endocrinology and Metabolism, Western University, London, Ontario, Canada.
  • Department of Endocrinology, Odense University Hospital, Odense, Denmark.
  • Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Endocrinology and Metabolism, Opsedale Regina Apostolorum, Albano Laziale, Rome, Italy.
  • Institute of Translational and Clinical Research, Newcastle University, Newcastle upon Tyne, UK.

ORCID-Profile: Laszlo Hegedüs, Endre V Nagy, Enrico Papini, Petros Perros, Roberto Attanasio, Roberto Negro, Stan Van Uum, Birte Nygaard, Steen J Bonnema, Kamilla R Riis

Förderung

  • This study was funded by a research grant from the Danish Medicines Agency, which had no role in the conceptualization, design, data collection, analysis, deci…

Zitieren

APA

Liu, A., Morrison, D., Hegedüs, L., Nagy, E. V., Papini, E., Perros, P., Attanasio, R., Negro, R., Van Uum, S., Nygaard, B., Bonnema, S. J., & Riis, K. R. (2025). Canadian Endocrinologists′ Perspectives on Treatment With Thyroid Hormone Substitutions in Euthyroid and Hypothyroid Patients: A 2023 THESIS Questionnaire Survey. Clinical Endocrinology. https://doi.org/10.1111/cen.70009

Vancouver

Liu A, Morrison D, Hegedüs L, Nagy EV, Papini E, Perros P, et al. Canadian Endocrinologists′ Perspectives on Treatment With Thyroid Hormone Substitutions in Euthyroid and Hypothyroid Patients: A 2023 THESIS Questionnaire Survey. Clinical Endocrinology. 2025. doi:10.1111/cen.70009

BibTeX
@article{Liu2025,
  author = {Liu, Anna and Morrison, Deric and Hegedüs, Laszlo and Nagy, Endre V and Papini, Enrico and Perros, Petros and Attanasio, Roberto and Negro, Roberto and Van Uum, Stan and Nygaard, Birte and Bonnema, Steen J and Riis, Kamilla R},
  title = {Canadian Endocrinologists′ Perspectives on Treatment With Thyroid Hormone Substitutions in Euthyroid and Hypothyroid Patients: A 2023 THESIS Questionnaire Survey},
  journal = {Clinical Endocrinology},
  year = {2025},
  doi = {10.1111/cen.70009}
}
Kostenlos starten →